Severe morbidity and mortality in untreated HIV-infected children in a paediatric care programme in Abidjan, Côte d'Ivoire, 2004-2009 by Desmonde, Sophie et al.
RESEARCH ARTICLE Open Access
Severe morbidity and mortality in untreated HIV-
infected children in a paediatric care programme
in Abidjan, Côte d’Ivoire, 2004-2009
Sophie Desmonde
1, Patrick Coffie
2, Edmond Aka
3, Clarisse Amani-Bosse
4, Eugène Messou
3, François Dabis
1,
Ahmadou Alioum
1, Andrea Ciaranello
5 and Valériane Leroy
1*
Abstract
Background: Clinical evolution of HIV-infected children who have not yet initiated antiretroviral treatment (ART) is
poorly understood in Africa. We describe severe morbidity and mortality of untreated HIV-infected children.
Methods: All HIV-infected children enrolled from 2004-2009 in a prospective HIV programme in two health
facilities in Abidjan, Côte d’Ivoire, were eligible from their time of inclusion. Risks of severe morbidity (the first
clinical event leading to death or hospitalisation) and mortality were documented retrospectively and estimated
using cumulative incidence functions. Associations with baseline characteristics were assessed by competing risk
regression models between outcomes and antiretroviral initiation.
Results: 405 children were included at a median age of 4.5 years; at baseline, 66.9% were receiving cotrimoxazole
prophylaxis, and 27.7% met the 2006 WHO criteria for immunodeficiency by age. The risk of developing a severe
morbid event was 14% (95%CI: 10.7 - 17.8) at 18 months; this risk was lower in children previously exposed to any
prevention of mother-to-child-transmission (PMTCT) intervention (adjusted subdistribution hazard ratio [sHR]: 0.16,
95% CI: 0.04 - 0.71) versus those without known exposure. Cumulative mortality reached 5.5% (95%CI: 3.5 - 8.1) at
18 months. Mortality was associated with immunodeficiency (sHR: 6.02, 95% CI: 1.28-28.42).
Conclusions: Having benefited from early access to care minimizes the severe morbidity risk for children who
acquire HIV. Despite the receipt of cotrimoxazole prophylaxis, the risk of severe morbidity and mortality remains
high in untreated HIV-infected children. Such evidence adds arguments to promote earlier access to ART in HIV-
infected children in Africa and improve care interventions in a context where treatment is still not available to all.
Background
In 2008, UNAIDS reported 14% of new human immu-
nodeficiency virus (HIV) infections occurring in children
below 15 years of age throughout the world [1]. By the
end of 2008, it was estimated that 91% of HIV-infected
children lived in sub-Saharan Africa [1]. Before ART
was introduced, infant mortality of HIV-infected chil-
dren on the African continent was high and premature,
reaching 35% among children less than 12 months of
age and 52% among children aged less than 24 months
[2]. While the rate of new paediatric infections has
slowly declined, only 38% of infected children have
access to antiretroviral therapy (ART), with a huge het-
erogeneity between world regions [3]. In Côte d’Ivoire,
the paediatric pandemic is sustained by a high preva-
lence of HIV among pregnant women (6.4%) [1], who,
despite increasing access to mother-to-child transmis-
sion prevention (PMTCT) programmes, transmit the
disease to their children [4].
In addition, providing a continuum of care between
postnatal HIV diagnosis and paediatric care remains
challenging, especially in Côte d’Ivoire [3-6], and the
uptake of early infant diagnosis remains fairly poor.
Thus, children are diagnosed belatedly, and when the
HIV diagnosis is eventually made, the antiretroviral
needs are not sufficiently met, estimated to reach only
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and premature mortality before any access to ART
[7-10].
In Africa, data on the disease progression of HIV-
infected children before access to ART are rare, frag-
mented and most often obtained from selected children
who have survived early opportunistic pathologies and
who are therefore selected for these reasons [7-14]. In
addition, the scarce existing data were collected during
time periods when ART access was limited or nonexis-
tent, when practices of care may have differed from the
current standards of care in Côte d’Ivoire[11].
Detailed and accurate data on clinical evolution of
HIV-infected children not on ART are essential in order
to evaluate the effect of HIV care and treatment now
being provided and to measure its effectiveness in the
field as ART access is being scaled up [15]. In this
paper, we describe the clinical evolution of HIV-infected
children who have not yet initiated ART, assessed by
severe morbidity and mortality and its determinants
before access to ART, in a paediatric HIV-care pro-
gramme in Abidjan, Côte d’Ivoire.
Methods
Study design and participants
In 2001, the Aconda Programme, a non-governmental
association comprised mainly of health professionals,
was implemented in Côte d’Ivoire. The main objective
of this programme is to provide HIV and antiretroviral
care in HIV-infected patients (adults and children)
[3,16]. In 2004, Aconda, in partnership with the Institute
of Public Health, Epidemiology and Development
(ISPED, Bordeaux, France), launched a five-year pro-
gramme of access to HIV care and treatment. ART was
delivered according the 2006 WHO guidelines. The pae-
diatric Aconda programme relies mostly on the two fol-
lowing HIV care centres: the paediatric CePReF site
(C e n t r ed eP r i s ee nc h a r g e ,d eR e c h e r c h ee td eF o r m a -
tion) which follows-up one of the largest active paedia-
tric ART cohorts in Abidjan [3] and the MTCT-Plus
programme, entirely dedicated to paediatric care follow-
ing the enrolment of HIV-infected pregnant and post-
partum women. Children included in the latter are, as a
consequence, diagnosed earlier than in other sites [17].
Our work was a retrospective study conducted within
the prospective assembly of a cohort of HIV-infected
children who had not yet initiated ART and who were
being followed-up in one of the two model paediatric
health facilities in the Aconda care programme in Abid-
jan. All children under 15 years of age with a medical
record who had not yet initiated any form of ART other
than PMTCT interventions and who were enrolled in
the programme between 1
st January 2004 and 31
st
December 2009 after a confirmed HIV diagnosis by
positive PCR at any age - or by positive serology if aged
over 18 months - were included in this study.
Data collection
The data collection took place retrospectively, from the
CePReF and MTCT pre-existing databases. However,
the CePReF database was not thorough and most of the
data were extracted from the medical files. A standar-
dised data collection instrument was issued for this pur-
pose. The following variables were recorded into a
database: date of inclusion, sex, date of birth, parental
HIV status, parental vital status, date and method of
diagnosis, HIV-diagnosis, PMTCT history, feeding his-
tory; date, height and weight; dates and causes of hospi-
talisation; dates and reason for treatment for in-patient
daycare; dates and AIDS-defining morbid events; dates
and receipts for cotrimoxazole, date and motif for can-
cellation of the prophylaxis; date of ART initiation;
dates and results of haematology and CD4 cell count
and percentage; and current status (transferred, LTFU,
on ART, deceased or still known to be alive and not
treated by ART).
Event classification during follow-up
Data regarding all clinical examinations, in-patient day-
care, and hospitalisations were extracted from the
patients’ medical records. The morbid events were
defined and classified in the following ways: cases of
respiratory tract infections, malnutrition, diarrhoea,
tuberculosis, chronic HIV-associated lung disease, anae-
mia, encephalopathy and other AIDS-defining events
were defined according to the WHO case definitions of
HIV surveillance [18]. Other frequent paediatric infec-
tious diseases such as varicella-zoster infections,
measles, hepatitis B and malaria were defined according
to the Red Book of Paediatrics [19]. Clinical events
belonging to stages 1&2 of the WHO classification were
not considered, neither were traumatic injuries. We
defined any morbid event as severe if it led to one of
the following: hospitalisation, in-patient daycare for
more than 48 hours, or death.
Statistical analysis
Baseline categorical data are presented as frequencies
(%), and continuous data as median (interquartile range,
(IQR)). Baseline differences between age groups and
immunodeficiency status, according to the 2006 WHO
recommendations (<15% if aged < 5 years; <200/mm
3 if
aged ≥ 5 years) [19], were compared with Chi-2 tests,
Fisher’s exact tests, t-tests or Wilcoxon’st e s t sw h e r e
appropriate. We used the 2006 guideline definitions to
be consistent with the study period, 2004-2009. The fol-
low-up period was defined as the time between enrol-
ment in the Aconda programme (time origin) and the
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death or date of last known to be alive). Two outcomes
were assessed during this follow-up period: 1) the first
severe morbid event and 2) mortality. The distributions
of time to these outcomes were estimated using compet-
ing risk survival analysis. ART initiation is a competing
cause of failure since children under ART have a better
chance of survival [20-22]. To avoid making unrealistic
assumptions about the independence of the outcomes,
w ec h o s et ou s eac u m u l a t i v ei n c i d e n c ef u n c t i o n( C I F )
to estimate the probabilities for each [23]. We ran a
multivariate competing risks analysis, performed by the
Fine and Gray proportional subdistribution hazard
regression model. We used the package cmprsk of R sta-
tistical software version 2.11.1 (The R foundation for
Statistical computing, Vienna, Austria) following guide-
lines presented by Scrucca et al [24,25]. If patients were
lost to follow-up, data were right-censored at the date
on which patients were last known to be alive (a patient
was considered lost to follow-up after a 6 month period
since the last clinical encounter).
Two multivariate models were estimated. In addition
to age, immunodeficiency status, and gender, the other
variables were inserted in the first “full” multivariate
model if their p-value was less than 0.25. A second,
“reduced” multivariate model was obtained from these
same variables using descending stepwise procedures.
The adjusted subdistribution hazard ratios were
reported with their 95% confidence intervals (95%CI).
Variables for which fewer than 70% of the patients pro-
vided data were not included. A p-value less than 0.05
was considered statistically significant on multivariate
analysis in both “full” and “reduced” models.
Ethical aspects
The national ethics committee of Côte d’Ivoire approved
the Aconda programme data management system
Results
Overall, 462 children fulfilled the inclusion criteria (Fig-
ure 1). Of these children, 57 (12.3%) were excluded
because no medical record could be located, leaving 405
children included in the analysis.
Characteristics of patients at baseline
The baseline characteristics of the 405 included children
are presented in Table 1. Children were diagnosed at a
median age of 4.5 years (IQR: 1.9; 7.5), and 47% were
females. The median age of enrolment was lower
amongst the children followed up in the MTCT pro-
gramme (1.7 years (IQR: 0.1;4.9) vs 5.4 years
(IQR:2.7;8.1), p <0.0001). Cotrimoxazole prophylaxis had
been prescribed to 67% of the children before enrolment
in the programme. The median weight for age z-score
(WAZ) was -2.09 (IQR: -3.45;-0.95) among the children
for whom anthropometric data were available. Approxi-
mately 50% of these children were suffering from failure
to thrive (FTT), defined as a WAZ < -2. Immunological
data (CD4 percent or count) were available for 308 chil-
dren (76.1%). Of these children, 27.7% met the 2006
WHO criteria for immunodeficiency by age. The pro-
portion of immunosuppressed children was highest
amongst the 10-15 year olds (55%, p <0.0001).
Patient follow-up
Among the 405 children included, the overall median
pre-ART follow-up time was 12 months (IQR: 1.3;30.6).
Over the study period, 240 (59.1%) initiated ART, 21
(5.2%) died, 41 (10%) were lost to follow-up, 11 (2.7%)
transferred to other healthcare facilities and 92 (23%)
were still known to be alive and untreated at the end-
point date (Figure 1).
Morbidity
Forty-two percent (170 children) presented with at least
one HIV-related condition during follow-up. Fifty-six
children (14%) presented with a first severe morbid
event during the first 18 months of follow-up, most fre-
quently malaria (37.5%) and WHO stage 3 events
(28.3%). Of these severe morbid events, 16 (28.6%) led
to death (Table 2). The observed incidence density rate
of occurrence of the first severe event was 17.8 per 100
child-years of follow-up. From the date of enrolment in
the programme, the overall median time of infection
until occurrence of the first severe event was 9.1 months
(IQR: 1.2;26.3). The probability of developing a first
severe morbid event at 18 months was high, with an
overall cumulative incidence of 11% (95%CI: 10.9;11.1).
During these first 18 months of follow-up (Figure 2),
the probability did not differ significantly by age at
enrolment nor by immune status (p = 0.51 and p = 0.87
respectively). Univariate analysis show that children in
the MTCT programme were less at risk of a first severe
event occurring than those in the CePReF programme
(sHR: 0.43, 95%CI:0.19;1), (Table 3). However, this asso-
ciation did not remain in the full multivariate model
(Table 3), due to correlation between the age and pro-
gramme variables (children in the MTCT programme
were younger). Associations between baseline character-
istics and the occurrence of the first severe event were
not seen in the full model, but the reduced model sug-
gested a lower risk in children ≥5 years of age at enrol-
ment compared to those <5 years of age (5-10 years,
sHR: 0.30, 95%CI: 0.10;0.97 and 10-15 years, SHR: 0.15,
95%CI:0.03;0.66). This association was confounded by
PMTCT interventions and immunodeficiency status,
however. The reduced model also showed a lower risk
in children previously exposed to any kind of PMTCT
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not exposed).
Mortality
By the end of the study, 21 deaths were recorded, 90.5%
of which occurred at home; the median time to death
was 12 months (IQR:1.5;30.8) and the incidence density
rate was estimated as 3.26 per 100 child-years of follow-
up (95%CI: 3.12;3.39). Fifty-two percent of the deaths
occurred in children aged less than 2 years. The
mortality rates for children aged 0-1 and 1-2 years were
9.70 and 3.41 per 100 child-years of follow-up, respec-
tively (Table 1).
The overall cumulative mortality reached 5.5% (95%CI:
5.3;5.7) at 18 months; reaching 14% at 18 months of fol-
low-up among children less than 12 months (p = 0.023)
(Figure 3A). Immunosuppressed children also had a
higher probability of death at 18 months compared to
non-immunosuppressed children (4.5%, 95%CI: 1.8;9.7,
vs 0.6%; 95%CI: 0.2;4.0). In addition, the absence of
  
INELIGIBLE 
ART initiated before 1st January 2004 
(n=143) 
Unknwon diagnosis date (n=48) 
Diagnosed after 1
st December 2009 
(n=72) 
Infected with HIV-2 alone (n=20) 
INELIGIBLE 
ART initiated before 1st January 2004 
(n=25) 
ELIGIBLE CHILDREN (n= 462) 
CePReF (n=370) 
MTCT     (n=92) 
EXCLUDED 
Missing medical record (n = 57) 
INCLUDED IN THE STUDY (n= 405) 
CePReF (N=313) 
MTCT     (N=92)  
Initiated ART (n=186)  Initiated ART (n=54) 
Lost to follow-up (n=34) * 
Deaths (n=15) 
Lost to follow-up (n=7)* 
Deaths (n=6) 
Transferred out (n=11)
HIV-infected children in the 
CePReF database 
n= 653 
HIV-infected children in the  
MTCT–Plus database 
n= 117 
Alive and untreated (n=67) Alive and untreated (n=25)
CePReF clinic MTCT – Plus clinic
Figure 1 Cohort profile of children included in the paediatric Aconda programme. Children followed up at the CePReF and in the MTCT-
Plus programme, Abidjan, Côte d’Ivoire (January 2004 - December 2009) *Missing data = date of HIV diagnosis unknown or missing medical
record; †Lost to Follow-up: last clinical contact > 6 months.
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unknown immunologic status had the highest risk of
death by 18 months: 13.6% (95%CI: 7.7;21.4; Figure 3B).
Adjusted for gender and immune status, age was no
longer associated with death (p = 0.07), but immune-
supression remained a significant predictor of death
(sHR: 6.02, 95% CI: 1.28;28.42), (Table 4).
Discussion
This cohort study from Abidjan, Côte d’Ivoire, docu-
ments patterns of severe morbidity and mortality in
HIV-1 infected children before the initiation of ART, in
a paediatric care programme in which ART access was
being scaled-up. There are two primary findings. First,
the risk of severe morbidity before ART initiation is
high, reaching 11% at 18 months. The risk of first ser-
ious morbidity was minimised in older children but also
by having received any intervention for PMTCT. Sec-
ond, the risk of mortality before ART initiation is high
(reaching 8% at 18 months), and this risk is greater in
immunosuppressed children and children with
unavailable immunological data. Importantly, the results
from this cohort study may underestimate the true risks
of morbidity and mortality, as they were derived from a
selected population included in research programmes,
where healthcare support might have been better than
that offered outside of the Aconda context.
In addition, our results highlight the impact of age at
enrolment. The overall incidences of severe morbidity
after 18 months of follow-up do not vary by immune
status but by age, which is consistent with a rapid CD4
evolution in the younger children. As the children fol-
lowed up in the MTCT programme are significantly
younger, there is a strong correlation between age and
follow-up centre; we therefore chose, in the reduced
model, to exclude the centre variable from the analyses.
Adjusting for PMTCT, immunosupression and gender
had an effect on the age variable in the final reduced
model; children aged ≥5w e r el e s sa tr i s ko fp r e s e n t i n g
with a first morbid event. Exposure to PMTCT inter-
ventions was more frequent among the younger children
and therefore the two variables were confounded. Based
Table 1 Characteristics by age in untreated HIV-infected children
Overall Age < 1 year Age 1 - 2
years
Age 2 - 5
years
Age 5 - 10
years
Age 10 - 15
years
BASELINE N = 405 N = 64 N = 42 N = 108 N = 142 N = 49
Age, years, median (IQR) 4.5 (1.9; 7.5) 0.3 (0.01; 0.6) 1.7 (1.6; 1.8) 3.4 (2.6; 4.1) 7 (5.9; 8.5) 12.1 (11.2;
13.1)
Female, n (%) 189 (46.7) 30 (46.9) 19 (45.2) 47 (43.5) 75 (52.8) 18 (36.7)
Weight available, n (%) 383 (94.6) 59 (92.2) 37 (88.1) 100 (92.6) 138 (97.2) 49 (100.0)
Height available, n (%) 369 (91.1) 59 (92.2) 36 (85.7) 95 -88 131 (92.3) 48 (97.9)
Weight for age z-score, median
(IQR)
-2.09 (-3.45;
-0.95)
-
1.94
(-3.01;
-0.91)
-2.67 (-4.10;
-1.60)
-1.93 (-3.36;
-0.74)
-1.84 (-3.22;
-0.75)
-2.58 (-4.05;
-1.62)
Height for age z-score, median
(IQR)
-1,59 (-2;69;
-0.76)
- -1.34 (-1.47;
-0.93)
-1.79 (-3.01;
-0.74)
-1.32 (-2.44;
-0.72)
-1.88 (-2.79;
-1.06)
Weight for height z-score,
median (IQR)
-1,11 (-2.63;
-0.21)
- -1.33 (-1.32;
-0.38)
-0.86 (-2.37;
0.06)
-1.38 (-3.57;
-0.43)
-1.67 (-1.85;
-1.49)
Failure to thrive, n (%) 198 (51.7) 29 (49.2) 26 (70.3) 48 -48 63 (45.7) 32 (65.3)
CD4 count measurement available,
n (%)
308 (76.1) 36 (56.3) 36 (85.7) 92 (85.2) 106 (74.6) 38 (94)
CD4 cell %, median (IQR) 19 (14; 25.5) 18.3 (14.1; 26) 17.9 (11.7;
23.3)
20.7 (14; 26.2) - -
CD4 count/μL, median (IQR) 403 (151; 665) - - - 507.5 (234; 723) 213.5 (55; 413)
Immunodepressed* children*, n
(%)
112 (27.7) 10 (15.6) 10 (15.6) 26 (24.1) 39 (27.5) 27 (55.1)
CDC stage C, n (%) 50 (12.3) 7 (10.9) 6 (14.3) 12 (11.1) 14 (9.9) 11 (2.1)
Baseline cotrimoxazole prophylaxis
n (%)
271 (66.9) 23 (35.9) 33 (78.6) 74 (68.5) 102 (71.8) 39 (67.4)
Born to known HIV-infected
mothers
273 (67.4) 64 (100) 33 (78.6) 86 (76.6) 77 (54.2) 13 (26.5)
Diagnosis by PCR before 18 months 71 (19.2) 53 (82.8) 6 (14.3) 5 (4.6) 6 (4.2) 1 (2.1)
Mother deceased at inclusion, n (%) 97 (30.9) 1 (1.6) 1 (2.4) 15 (13.9) 52 (36.6) 28 (57.1)
Breastfeeding history, n (%) 191 (47.2) 40 (62.5) 19 (45.2) 43 (39.9) 67 (47.2) 22 (44.9)
History of PMTCT intervention 65 (18.1) 50 (78.1) 10 (23.8) 5 (4.6) - -
Children followed-up by the CePReF and the MTCT-Plus programme, Abidjan, Côte d’Ivoire (January-2004-December 2009). n = 405. * Immunodeficiency
according to the 2006 criteria;
Desmonde et al. BMC Infectious Diseases 2011, 11:182
http://www.biomedcentral.com/1471-2334/11/182
Page 5 of 12on previous studies reporting PMTCT interventions as
having a protective effect on severe morbidity [26,27],
we expected to observe a lower risk of severe morbidity
among the younger children. However, our study shows
higher risks among these children. We hypothesise that
the outcomes of PMTCT interventions are not the only
explanation for the observed results, but the available
data does not allow further conclusions; PMTCT is a
marker of early and different access to care for younger
children than for older children. We show here the posi-
tive effect of early access to care on reducing the risk of
occurrence of the first severe HIV-related morbid event.
These results highlight the importance of comprehen-
sive HIV care in addition to ART. Despite prophylaxis
by cotrimoxazole at baseline to prevent opportunistic
infections [28], substantial morbidity attributable to
other co-infectious disease (bacterial, viral and parasitic
infections) was observed. Optimal prevention and care
for comorbidities needs to be investigated before and
after ART access to improve paediatric care.
Mortality was moderate in this cohort, reaching 8% at
18 months. Although mortality risk was significantly
higher among infants < 12 months than among older
infants in univariate analyses, we found no overall signif-
icant effect of age in multivariate analyses. There was,
however, a 12-fold increase in mortality risk for children
who had no CD4 measurement. Infants aged < 12
months have previously been reported to have higher
risk for death and loss to follow-up than older children
[6]; among infants <12 months old in our cohort, 50%
had no available CD4% data at baseline. This correlation
between young age and unavailable CD4% partially
explains the observed increased risk of mortality in chil-
dren without CD4% data. The reasons for this lack of
CD4% availability in younger children are also critical.
Children diagnosed as HIV-infected and then enrolled
in the clinic often have to return on a different date for
CD4 measurement if no staff members are available for
phlebotomy at the initial visit. While most of these chil-
dren do return, many others are lost to follow-up. Rea-
sons for loss-to-follow-up remain a primary research
question in paediatric care, but in light of these results,
we can hypothesise that many deaths occurring at home
during the interval before the scheduled return visit, and
then are reported to the clinic at a later date when con-
tacted by a care worker. This demonstrates the critical
need for improved and expedited linkage to care
between diagnosis, CD4% measurement, and ART
initiation.
There are two important limitations inherent in our
study design. First, the timing of paediatric HIV infec-
tion could not be known with complete accuracy. In
Abidjan, like in most resource limited settings, social
barriers and stigma associated with HIV/AIDS often
lead to delays in accessing care and in receipt of HIV
diagnosis. The youngest children in our study were
Table 2 Distribution of the first severe morbid event in untreated HIV-infected children
Diagnosis Number of first events, n(%) Lethal events, n(%)
WHO Stage 2
Hepatosplenomegaly 1 (1,7) -
WHO Stage 3
Failure to thrive (FTT) 2 (3,6) 1 (50)
Unexplained persistent diarrhoea 4 (7,1) -
Unexplained persistent fever 1 (1,7) -
Tuberculosis 1 (1,7) 1 (100)
Chronic lung disease 4 (7,1) -
Severe bacterial infections 4 (7,1) 2 (50)
WHO Stage 4
Pneumonia 1 (1,7) -
Other diagnosis of interest
Malaria 21 (37,5) -
Meningitis 2 (3,6) 2 (100)
Unknown 15 (26,7) 10 (67)
Total 56 (100) 16 (28,6)
Children followed-up over 18 months by the CePReF and the MTCT-Plus programme, Abidjan, Côte d’Ivoire (January-2004-December 2009). n = 405.
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time of infection (antepartum, intrapartum, or postnatal)
is not documented, we could reasonably estimate the
time of infection as being the date of birth. However,
older children in this cohort may have been infected
perinatally, or they may have been exposed to HIV by
blood transfusion, sexual activity or hospital-acquired
infections. These children are mostly followed up in the
CePReF programme, having been diagnosed with HIV-1
following a severe opportunistic infection; their time of
infection cannot be estimated with the available data.
Furthermore, mortality is severe amongst infants in the
absence of ART [4], which combined with the late diag-
noses issues, induces a strong left truncation phenom-
enon [29]. To address this left-censoring of the data, we
modelled infection from the date of enrolment in the
healthcare programme, stratifying by age. Thus, the
information observed over different age groups provides
a detailed estimate of clinical disease progression in pre-
valent cohorts for older children, but could be consid-
ered as the clinical disease progression of perinatally
infected children for those aged less than 5 years.
Second, morbidity and mortality may have been
incompletely ascertained. Many African families with-
hold information concerning infection and diagnosis, as
well as information relative to prior events and deaths
during follow-up [30]. In addition, missing data arose as
a result of the reality of healthcare services in the field
in Africa and the lack of follow-up in clinical examina-
tions. The data coming from the pre-existing MTCT
datasets were precise, as they derive from previous
research programmes, but most of the data from the
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Figure 2A
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Figure 2 Cumulative incidence functions for first severe morbidity by age (2A) and immunodeficiency status (2B). Children followed up
at the CePReF and in the MTCT-Plus programme, Abidjan, Côte d’Ivoire (January 2004 - December 2009). n = 405.
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Page 7 of 12CePReF, which represents 77% of the children, was col-
lected retrospectively by the means of a standardised
collection instrument. Record-keeping practices may
vary over time and between providers. As a conse-
quence, diagnoses could not be confirmed using stan-
dardised diagnosis procedures. We attempted to ensure
the accuracy of clinical events by requiring documenta-
tion, such as clinical findings, laboratory examinations,
and radiographic results. However, this may have led to
under-documentation of the true rate of clinical events.
This could explain, in part, the observed lower risk of
severe morbidity in the older children. Moreover, the
morbidity observed must be interpreted with caution.
Not only are the diagnoses not confirmed, but there is
no control group of non-HIV-infected children with
whom to compare specific morbidity rates. Nonetheless,
we show here a high rate of overall severe and avoidable
morbidity despite prophylaxis in HIV-infected children
who do not have access to ART.
In addition to morbidity, the infant mortality rate in
this cohort may be underestimated. Many events leading
to death remain undetermined. These unknown causes
of death are frequent because most deaths occurred at
home; these deaths were most likely reported to the
clinic only in response to a follow-up call made by a
care worker. We also suspect that a substantial propor-
tion of the children lost to follow-up are in fact
deceased. Moreover, many of these children were immu-
nosuppressed according to the 2006 WHO criteria,
which is a known predictor of death. Nevertheless, the
overall loss to follow up rate was only 11% at 18
months; even taking into account the exclusion of 12.3%
Table 3 Characteristics associated with the first severe morbidity during follow-up in untreated HIV-infected children
Univariate analysis Ajusted analysis
Full model Reduced model
Variable # patients # events Observed rate (/100 CY) sHR† 95%CI‡ sHR 95%CI P sHR 95%CI P
Overall 405 58 17.80
Age at baseline
(years)
0.54 0.39 0.07
< 1 64 7 12.78 1 - 1 - 1 -
[1 - 2] 42 7 20.36 1.29 (0.47-3.58) 0.45 (0.12 - 1.64) 0.52 (0.13 - 2.01)
[2 - 5] 108 17 20.41 1.24 (0.53 - 2.91) 0.43 (0.14 - 1.31) 0.42 (0.14 - 1.32)
[5 - 10] 142 21 16.65 0.94 (0.41 - 2.15) 0.38 (0.13 - 1.14) 0.30 (0.10 - 0.97)
[10 - 15] 49 4 14.58 0.45 (0.12 - 1.70) 0.23 (0.05 - 1.02) 0.15 (0.03 - 0.66)
Immunodeficiency 0.87 0.91 0.86
No 112 29 13.61 1 - 1 - 1 -
Yes 106 15 39.24 0.84 (0.43-1.63 0.88 (0.47 - 1.65) 0.84 (0.43 - 1.63)
Unknown 98 14 18.75 0.91 (0.46 - 1.77) 1.02 (0.54 - 1.93) 1.03 (0.51 - 2.07)
Gender 0.78 0.95 0.77
Male 216 32 18.07 1 - 1 - 1 -
Female 189 26 17.46 0.93 (0.54 - 1.60) 0.91 (0.54 - 1.58) 0.91 (0.51 - 1.61)
History of a PMTCT
intervention
0.11 0.19 0.05
No 267 41 21.72 1 - 1 - 1 -
Yes 65 5 7.41 0.43 (0.15 - 1. 02) 0.32 (0.06 - 1. 63) 0.16 (0.04 - 0.72)
Unknown 73 12 17.20 1.04 (0.53 - 2.02) 1.21 (0.56 - 2.59) 0.82 (0.42 - 1.59)
Mother known to be
deceased
0.13 0.26
No 308 48 18.19 1 - 1 -
Yes 97 10 16.10 1.78 (0.84 - 3.14) 1.51 (0.73 - 3.09)
Cotrimoxazole prophylaxis at baseline 0.35
No 134 17 15.60 1 -
Yes 271 41 18.89 1.33 (0.73 - 2.43)
Follow-up Centre 0.05 0.14
Cepref 131 50 21.92 1 - 1 -
MTCT 92 8 8.17 0.43 (0.18 - 1) 0.45 (0.16 - 1.29)
Children followed-up over 18 months by the CePReF and the MTCT-Plus programme, Abidjan, Côte d’Ivoire (January-2004-December 2009). n = 405. Fine and
Gray Model CY: Child Years; †sHR: subdistribution hazard ratio; ‡95% confidence interval
Desmonde et al. BMC Infectious Diseases 2011, 11:182
http://www.biomedcentral.com/1471-2334/11/182
Page 8 of 12of the eligible cohort for missing medical records (per-
haps also representing loss-to-follow-up), this rate of
missingness is low in the African context compared to
those of cohorts of children on ART [3,15,31].
Our study is the first to investigate pre-ART morbidity
and mortality in a large paediatric cohort with a wide
age distribution during the ART era, reflecting as well
as possible current care practices in Côte d’Ivoire
[8,32-34]. Several of our results are in keeping with pre-
vious findings, suggesting the validity of our results
despite the limitations described above. First, the mor-
tality documented in this cohort is in accord with the
bi-modal pattern of the paediatric HIV infection, mainly
characterised by early mortality. We report a mortality
rate three times higher in children aged less than 12
months than in older children, but the numbers remain
low compared to those of previous studies [34-37]. As
have shown recent studies, CD4 cell counts are impor-
tant indicators [38,39] of mortality in this analysis.
Our study first suggests low rates of death but high
rates of severe morbidity among non-ART treated HIV
infected children. Despite the efforts of implementing
antiretroviral access and PMTCT interventions in Abid-
jan, our results demonstrate still a high rate of infected
children who do not have access to ART. This justifies
the revision of the WHO guidelines recommending
ART to all infected children aged < 24 months regard-
less of CD4 count, but this is not always applied in the
  
Figure 3 Cumulative incidence functions for mortality by age (3A) and immunodeficiency status (3B).C h i l d r e nf o l l o w e du pa tt h e
CePReF and in the MTCT-Plus programme, Abidjan, Côte d’Ivoire (January 2004 - December 2009). n = 405
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Page 9 of 12field. In many resource-limited settings, ART coverage
remains low mainly for operational reasons, leading to
high mortality and morbidity. Additional paediatric clin-
ical research must be undertaken in order to measure
the incidence of mortality, morbidity, and loss to pro-
gramme in infected children before and after ART
access and the use of prophylactic treatment in opportu-
nistic infections. This would allow investigators to
model the evolution of the paediatric infection and mea-
sure the cost effectiveness of interventions with a final
goal to guiding care of children infected by HIV in
Africa, as has been done successfully in the past for
adults [40-42].
Conclusions
We describe clinical progression in untreated, HIV-
infected children in Abidjan, Côte d’Ivoire, in the con-
text of paediatric-specific HIV care. Having benefited
from early access to care minimizes the severe morbidity
risk for those children who acquire HIV. Despite the
receipt of cotrimoxazole prophylaxis, the risk of serious
morbidity and mortality remains high in ART-untreated
HIV-infected children. As such clinical events are likely
preventable by early initiation of ART to improve
immune status, these findings demonstrate the need to
promote an earlier access to ART in HIV-infected chil-
dren in Africa, in a context where early ART is officially
Table 4 Characteristics associated with mortality during follow-up in untreated HIV-infected children
Univariate analysis Ajusted analysis
Full model Reduced model
Variable #
patients
#
events
Observed rate (/100
CY)
sHR† 95%CI‡ P sHR 95%CI P sHR 95%CI P
Overall 405 21 3.26
Age at baseline
(years)
0.034 0.840 0.097
< 1 64 9 9.70 1 - 1 - 1 -
[1 - 2] 42 2 3.40 0.32 (0.07 - 1.48) 0.76 (0.08 - 6.38) 0.6 (0.11 - 3.23)
[2 - 5] 108 3 1.68 0.2 (0.05 - 0.74) 0.44 (0.07 - 2.70) 0.34 (0.08 - 1.39)
[5 - 10] 142 5 1.82 0.24 (0.08 - 0.71) 0.39 (0.06 - 2.31) 0.29 (0.10 - 0.80)
[10 - 15] 49 2 4.91 0.28 (0.06 - 1.29) 0.44 (0.05 - 4.26) 0.28 (0.06 - 1.19)
Immunodeficiency 0.001 0.003 0.0025
No 112 6 1.36 1 - 1 - 1 -
Yes 106 2 3.38 5.21 (1.00 -
25.60)
6.8 (1.51 -
30.57)
6.02 (1.28 -
28.42)
Unknown 98 13 8.90 13.82 (3.16 -
60.50)
12.93 (2.95 -
56.68)
12.6 (2.94 -
53.97)
Gender 0.920 0.770 0.670
Male 216 11 3.09 1 - 1 - 1 -
Female 189 10 3.45 1.05 (0.47 - 2.45) 1.15 (0.44 - 2.98) 1.22 (0.49 - 3.04)
History of a PMTCT
intervention
0.019 0.590
No 267 11 2.80 1 - 1 -
Yes 65 8 6.73 2.96 (1.19 - 7.33) 0.92 (0.14 - 6.21)
Unknown 73 2 1.48 0.63 (0.14 - 2.83) 0.47 (0.11 - 2.05)
Mother known to be
deceased
0.140 0.230
No 308 19 3.59 1 - 1 -
Yes 97 2 1.72 3.01 (0.71 -
12.80)
2.78 (0.53 -
14.68)
Cotrimoxazole prophylaxis at baseline 0.150 0.830
No 134 11 4.93 1 - 1 -
Yes 271 10 2.36 0.53 (0.23 - 1.25) 1.13 (0.37 - 3.43)
Follow-up Centre 0.550
Cepref 131 15 3.34 1 -
MTCT 92 6 3.05 1.33 (0.52 - 3.45)
Children followed-up over 18 months by the CePReF and the MTCT-Plus programme, Abidjan, Côte d’Ivoire (January-2004-December 2009). n = 405. Fine and
Gray Model. CY: Child Years; †sHR: subdistribution hazard ratio; ‡95% confidence interval
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Page 10 of 12recommended and is being scaled up, but is still not
available to a majority of children.
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